...
首页> 外文期刊>Journal of the American Chemical Society >Renal Clearable Ultrasmall Single-Crystal Fe Nanoparticles for Highly Selective and Effective Ferroptosis Therapy and Immunotherapy
【24h】

Renal Clearable Ultrasmall Single-Crystal Fe Nanoparticles for Highly Selective and Effective Ferroptosis Therapy and Immunotherapy

机译:肾可清除超细单晶Fe纳米粒子,用于高度选择性和有效的硬质菌疗法和免疫疗法

获取原文
获取原文并翻译 | 示例
           

摘要

Iron-based nanoparticles have attracted much attention because of their ability to induce ferroptosis via a catalyzing Fenton reaction and to further potentiate immunotherapy. However, current iron-based nanoparticles need to be used in cooperation with other treatments or be applied in a high dose for effective therapy because of their low reactive oxygen species production efficacy. Here, we synthesized ultrasmall single-crystal Fe nanoparticles (bcc-USINPs) that stayed stable in a normal physiological environment but were highly active in a tumor microenvironment because of the selective acidic etching of an Fe_3O_4 shell and the exposure of the Fe(0) core. The bcc-USINPs could efficiently induce tumor cell ferroptosis and immunogenetic cell death at a very low concentration. Intravenous injection of iRGD-bcc-USINPs at three doses of 1 mg/kg could effectively suppress the tumor growth, promote the maturation of dendritic cells, and trigger the adaptive T cell response. Combined with programmed death-ligand 1 (PD-L1) immune checkpoint blockade immunotherapy, the iRGD-bcc-USINP-mediated ferroptosis therapy greatly potentiated the immune response and developed strong immune memory. In addition, these USINPs were quickly renal excreted with no side effects in normal tissues. These iRGD-bcc-USINPs provide a simple, safe, effective, and selectively tumor-responsive Fe(0) delivery system for ferroptosis-based immunotherapy.
机译:铁基纳米粒子由于它们通过催化Fenton反应和进一步的增强免疫疗法而引起恶性裂菌的能力。然而,目前的铁基纳米粒子需要与其他治疗合作使用或者以高剂量施用,因为它们具有低活性氧物种生产疗效。在此,我们合成超大单晶Fe纳米颗粒(BCC-USINP),其在正常生理环境中保持稳定,但由于Fe_3O_4壳的选择性酸性蚀刻和Fe(0)的暴露,在肿瘤微环境中具有高度活性的核。 BCC-USINPS可以以非常低的浓度有效地诱导肿瘤细胞硬化和免疫萌发细胞死亡。静脉注射IRGD-BCC-USINPS的三剂量1mg / kg可以有效地抑制肿瘤生长,促进树突细胞的成熟,并引发适应性T细胞反应。结合编程死亡 - 配体1(PD-L1)免疫检查点阻断免疫疗法,IRGD-BCC-USINP介导的糖凋亡疗法大大提高了免疫应答并发生了强烈的免疫记忆。此外,这些USINPS在正常组织中迅速排出肾脏,没有副作用。这些IRGD-BCC-USINPS提供了一种简单,安全,有效,选择性的肿瘤响应性Fe(0)递送系统,用于基于嗜酸性病的免疫疗法。

著录项

  • 来源
    《Journal of the American Chemical Society》 |2021年第38期|15812-15823|共12页
  • 作者单位

    State Key Laboratory of Natural Medicines Key Laboratory of Drug Quality Control and Pharmacovigilance Department of Pharmaceutical Analysis China Pharmaceutical University Nanjing 211198 China;

    State Key Laboratory of Natural Medicines Key Laboratory of Drug Quality Control and Pharmacovigilance Department of Pharmaceutical Analysis China Pharmaceutical University Nanjing 211198 China;

    State Key Laboratory of Natural Medicines Key Laboratory of Drug Quality Control and Pharmacovigilance Department of Pharmaceutical Analysis China Pharmaceutical University Nanjing 211198 China;

    State Key Laboratory of Natural Medicines Key Laboratory of Drug Quality Control and Pharmacovigilance Department of Pharmaceutical Analysis China Pharmaceutical University Nanjing 211198 China;

    Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology Cambridge Massachusetts 02142 United States;

    State Key Laboratory of Natural Medicines Key Laboratory of Drug Quality Control and Pharmacovigilance Department of Pharmaceutical Analysis China Pharmaceutical University Nanjing 211198 China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号